185 related articles for article (PubMed ID: 9016935)
1. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor.
Knudsen LB; Pridal L
Eur J Pharmacol; 1996 Dec; 318(2-3):429-35. PubMed ID: 9016935
[TBL] [Abstract][Full Text] [Related]
2. Comparison of sandwich enzyme-linked immunoadsorbent assay and radioimmunoassay for determination of exogenous glucagon-like peptide-1(7-36)amide in plasma.
Pridal L; Ingwersen SH; Larsen FS; Holst JJ; Adelhorst K; Kirk O
J Pharm Biomed Anal; 1995 Jun; 13(7):841-50. PubMed ID: 8562607
[TBL] [Abstract][Full Text] [Related]
3. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects.
Deacon CF; Nauck MA; Toft-Nielsen M; Pridal L; Willms B; Holst JJ
Diabetes; 1995 Sep; 44(9):1126-31. PubMed ID: 7657039
[TBL] [Abstract][Full Text] [Related]
4. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
Kolligs F; Fehmann HC; Göke R; Göke B
Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.
Deacon CF; Knudsen LB; Madsen K; Wiberg FC; Jacobsen O; Holst JJ
Diabetologia; 1998 Mar; 41(3):271-8. PubMed ID: 9541166
[TBL] [Abstract][Full Text] [Related]
6. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor.
Montrose-Rafizadeh C; Yang H; Rodgers BD; Beday A; Pritchette LA; Eng J
J Biol Chem; 1997 Aug; 272(34):21201-6. PubMed ID: 9261127
[TBL] [Abstract][Full Text] [Related]
7. Value of the radiolabelled GLP-1 receptor antagonist exendin(9-39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans.
Waser B; Reubi JC
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1054-8. PubMed ID: 21210113
[TBL] [Abstract][Full Text] [Related]
8. Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7--36) amide.
Heller RS; Aponte GW
Am J Physiol; 1995 Dec; 269(6 Pt 1):G852-60. PubMed ID: 8572216
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.
Ebinger M; Jehle DR; Fussgaenger RD; Fehmann HC; Jehle PM
Am J Physiol Endocrinol Metab; 2000 Jul; 279(1):E88-94. PubMed ID: 10893327
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1(7-37) has a larger volume of distribution than glucagon-like peptide-1(7-36)amide in dogs and is degraded more quickly in vitro by dog plasma.
Pridal L; Deacon CF; Kirk O; Christensen JV; Carr RD; Holst JJ
Eur J Drug Metab Pharmacokinet; 1996; 21(1):51-9. PubMed ID: 8839678
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs.
Eng H; Sharma R; McDonald TS; Landis MS; Stevens BD; Kalgutkar AS
Xenobiotica; 2014 Sep; 44(9):842-8. PubMed ID: 24588343
[TBL] [Abstract][Full Text] [Related]
12. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
[TBL] [Abstract][Full Text] [Related]
13. Internalization of glucagon-like peptide-1(7-36)amide in rat insulinoma cells.
Göke R; Richter G; Göke B; Trautmann M; Arnold R
Res Exp Med (Berl); 1989; 189(4):257-64. PubMed ID: 2554438
[TBL] [Abstract][Full Text] [Related]
14. Rat parietal cell receptors for GLP-1-(7-36) amide: northern blot, cross-linking, and radioligand binding.
Schmidtler J; Dehne K; Allescher HD; Schusdziarra V; Classen M; Holst JJ; Polack A; Schepp W
Am J Physiol; 1994 Sep; 267(3 Pt 1):G423-32. PubMed ID: 7943240
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1(7-36)amide: characterization of the domain responsible for binding to its receptor on rat insulinoma RINm5F cells.
Gallwitz B; Schmidt WE; Conlon JM; Creutzfeldt W
J Mol Endocrinol; 1990 Aug; 5(1):33-9. PubMed ID: 2168708
[TBL] [Abstract][Full Text] [Related]
16. Characterization of receptors for glucagon-like peptide-1(7-36)amide on rat lung membranes.
Richter G; Göke R; Göke B; Arnold R
FEBS Lett; 1990 Jul; 267(1):78-80. PubMed ID: 2163902
[TBL] [Abstract][Full Text] [Related]
17. Developmental patterns of glucagon-like peptide-1-(7-36) amide and peptide-YY in rat pancreas and gut.
Kreymann B; Ghatei MA; Domin J; Kanse S; Bloom SR
Endocrinology; 1991 Aug; 129(2):1001-5. PubMed ID: 1677327
[TBL] [Abstract][Full Text] [Related]
18. Allosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptor.
Li N; Lu J; Willars GB
PLoS One; 2012; 7(10):e47936. PubMed ID: 23094100
[TBL] [Abstract][Full Text] [Related]
19. Dual glucagon recognition by pancreatic beta-cells via glucagon and glucagon-like peptide 1 receptors.
Moens K; Flamez D; Van Schravendijk C; Ling Z; Pipeleers D; Schuit F
Diabetes; 1998 Jan; 47(1):66-72. PubMed ID: 9421376
[TBL] [Abstract][Full Text] [Related]
20. Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C.
Wheeler MB; Lu M; Dillon JS; Leng XH; Chen C; Boyd AE
Endocrinology; 1993 Jul; 133(1):57-62. PubMed ID: 8391428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
